Virios Therapeutics Llc
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for… Read more
Virios Therapeutics Llc (VIRI) - Total Liabilities
Latest total liabilities as of June 2024: $500.07K USD
Based on the latest financial reports, Virios Therapeutics Llc (VIRI) has total liabilities worth $500.07K USD as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Virios Therapeutics Llc - Total Liabilities Trend (2018–2023)
This chart illustrates how Virios Therapeutics Llc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Virios Therapeutics Llc Competitors by Total Liabilities
The table below lists competitors of Virios Therapeutics Llc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MS&AD INSURANCE
MU:59M
|
Germany | €22.45 Trillion |
|
OCEANEERING INTL
BE:OII
|
Germany | €1.65 Billion |
|
REGIONS FINANCIAL (RN7.SG)
STU:RN7
|
Germany | €138.70 Billion |
|
Antiaging Quantum Living Inc.
PINK:AAQL
|
USA | $3.24 Million |
Liability Composition Analysis (2018–2023)
This chart breaks down Virios Therapeutics Llc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Virios Therapeutics Llc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Virios Therapeutics Llc (2018–2023)
The table below shows the annual total liabilities of Virios Therapeutics Llc from 2018 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $358.55K | -65.63% |
| 2022-12-31 | $1.04 Million | -18.22% |
| 2021-12-31 | $1.28 Million | -16.73% |
| 2020-12-31 | $1.53 Million | -70.87% |
| 2019-12-31 | $5.26 Million | +296.46% |
| 2018-12-31 | $1.33 Million | -- |